Tamás Masszi
A5087934925- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Peptidase Inhibition and Analysis
- Eosinophilic Disorders and Syndromes
- Acute Lymphoblastic Leukemia research
- Cancer Treatment and Pharmacology
- Kruppel-like factors research
- Complement system in diseases
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Hemoglobinopathies and Related Disorders
- Platelet Disorders and Treatments
- Immune Cell Function and Interaction
- Cancer therapeutics and mechanisms
- Cancer Genomics and Diagnostics
- Cancer Mechanisms and Therapy
- Monoclonal and Polyclonal Antibodies Research
- Blood disorders and treatments
- Histone Deacetylase Inhibitors Research
- Ubiquitin and proteasome pathways
Semmelweis University
2016-2025
City Of Hope National Medical Center
2023
Hungarian Research Network
2023
City of Hope
2023
Translational Genomics Research Institute
2023
Fox Chase Cancer Center
2023
Unified Szent István and Szent László Hospital
2011-2020
European Society for Blood and Marrow Transplantation
2017
University Hospital Brno
2016
General University Hospital in Prague
2016
Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, well combination bortezomib newly diagnosed myeloma.In this phase 3 trial, we randomly assigned 498 relapsed or refractory myeloma to receive (1.3 mg per square meter of body-surface area) dexamethasone (20 mg) alone (control group) daratumumab (16 kilogram body weight)...
Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and has shown efficacy in phase 1 2 study
Ixazomib is an oral proteasome inhibitor that currently being studied for the treatment of multiple myeloma.
Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have clinical benefit in patients with polycythemia vera phase study. We conducted 3 open-label study evaluate the efficacy safety of ruxolitinib versus standard therapy who had an inadequate response or unacceptable side effects from hydroxyurea.We randomly assigned phlebotomy-dependent splenomegaly, 1:1 ratio, receive (110 patients) (112 patients). The primary end point both hematocrit control through week 32 at least 35%...
Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life threatening complication that can develop after hematopoietic cell transplantation. Although SOS/VOD progressively resolves within few weeks in most patients, the severe forms result multi-organ dysfunction and are associated with high mortality rate (>80%). Therefore, careful attention must be paid to allow an early detection of SOS/VOD, particularly drugs have now proven effective...
Peripheral T-cell lymphomas (PTCLs) represent a diverse group of non-Hodgkin with poor prognosis and no accepted standard care for patients relapsed or refractory disease. This study evaluated the efficacy tolerability belinostat, novel histone deacetylase inhibitor, as single agent in PTCL.Patients confirmed PTCL who experienced progression after ≥ one prior therapy received belinostat 1,000 mg/m(2) daily 30-minute infusions on days 1 to 5 every 21 days. Central assessment response used...
IMPORTANCE Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm characterized by anemia, splenomegaly, debilitating constitutional symptoms, and shortened survival.Fedratinib, JAK2-selective inhibitor, previously demonstrated clinically beneficial activity in patients with MF early-phase trials.OBJECTIVE To evaluate the efficacy safety of fedratinib therapy primary or secondary (post-polycythemia vera post-essential thrombocythemia) MF.DESIGN, SETTING, AND PARTICIPANTS...
The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with Philadelphia chromosome-positive chronic myeloid leukemia in MR4.5 (BCR-ABL1⩽0.0032% on International Scale (BCR-ABL1IS)) and ⩾2 years of therapy were enrolled. sustained deep during 1-year consolidation eligible stop treatment enter TFR phase. loss major (MMR;...
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus alone the primary analysis of CASTOR, phase 3 study relapsed and/or refractory multiple myeloma. A post hoc based on treatment history longer follow up is presented. After 19.4 (range: 0-27.7) months median up, daratumumab plus prolonged progression-free survival (median: 16.7 7.1 months; hazard ratio, 0.31; 95% confidence interval, 0.24-0.39;...
Objectives Uncontrolled thromboinflammation plays an important role in the pathogenesis of coronavirus disease (COVID-19) caused by SARS-CoV-2 virus. Complement was implicated as key contributor to this process, therefore we hypothesized that markers complement profile, indicative for activation state system, may be related severity and mortality COVID-19. Methods In prospective cohort study samples 102 hospitalized 26 outpatients with PCR-confirmed COVID-19 were analyzed. Primary outcome...
At the primary analysis of CASTOR (median follow-up, 7.4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged progression-free survival versus (Vd) alone in relapsed or refractory multiple myeloma (RRMM). We report updated efficacy safety results at final for overall (OS).CASTOR was a multicenter, randomized, open-label, phase III study during which eligible patients with ≥ 1 line prior therapy were randomly assigned to Vd (up eight cycles) without (until...
This prospective multicenter phase III study compared the efficacy and safety of a triple combination (bortezomib-thalidomide-dexamethasone [VTD]) versus dual (thalidomide-dexamethasone [TD]) in patients with multiple myeloma (MM) progressing or relapsing after autologous stem-cell transplantation (ASCT).Overall, 269 were randomly assigned to receive bortezomib (1.3 mg/m(2) intravenous bolus) no for 1 year, thalidomide (200 mg per day orally) dexamethasone (40 orally once on 4 days every 3...
Long-term outcome after hematopoietic stem cell transplantation including late transplant-related events is of increasing interest. The aim this study was to evaluate the incidence cardiovascular allogeneic HSCT and search for their risk factors.This a retrospective multicenter European Group Blood Marrow Transplantation (EBMT) analysis, 548 long-term survivors treated in ten EBMT transplant centers, who underwent between 1990 1995 survived >or=1 year transplant. All arterial occurring...
Purpose To assess bortezomib plus melphalan and prednisone (VMP) (MP) in previously untreated patients with multiple myeloma (MM) renal impairment enrolled on the phase III VISTA study, to evaluate reversibility. Patients Methods received nine 6-week cycles of VMP (bortezomib 1.3 mg/m 2 , 9 60 ) or MP. serum creatinine higher than mg/dL were excluded. Results In VMP/MP arms, 6%/4%, 27%/30%, 67%/66% had baseline glomerular filtration rate (GFR) ≤ 30, 31 50, 50 mL/min, respectively. Response...
Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or busulfan (Bu) are currently the most common myeloablative regimens used in allogeneic stem-cell transplantation (alloSCT) adults acute myelogenous leukemia (AML). Intravenous (IV) Bu has more predictable bioavailability and a safer toxicity profile than oral formulation. Comparative studies of outcomes have been performed between Bu/Cy Cy/TBI, but there no comparative trials era IV Bu.We retrospective registry-based study...
RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant or intolerant patients with polycythemia vera. This preplanned analysis occurred when all completed Week 80 visit discontinued. Objectives included durability of primary response (Week 32 phlebotomy-independent hematocrit control plus ≥35% spleen volume reduction), its components, and that complete hematologic...